40% Patients Suffer Relapse Within 18 Months ...

Inside Fleur Marks’ extraordinary story of burnout, illness and survival, and how she learned to “show up for life” despite ...

An international research team has succeeded in elucidating key immunological and biochemical mechanisms underlying ...

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chron ...

Dr Anjali Pathak on how granuloma annulare may be overlooked and how to identify and manage this unusual skin condition ...

IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); ...

aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...

TheFly reported that QNCX presented Phase 2a clinical results for LAM-001 on May 18, at the American Thoracic Society ...

Detailed price information for Atyr Pharma Inc (ATYR-Q) from The Globe and Mail including charting and trades.

Among adults with both obesity and an autoimmune disease, those taking a glucagon-like peptide-receptor 1 agonist (GLP-1RA) ...

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the 15 High Growth Stocks to Buy and Hold for the Next Decade. On May 21, 2026, TD Cowen raised the firm’s price target on Roivant Sciences Ltd.

During the quarter ended March 31, 2026, Baron Health Care Fund® (the Fund) declined 6.97% (Institutional Shares), compared ...